Active Ingredient(s):Idarucizumab FDA Approved: * October 16, 2015 Pharm Company: *BOEHRINGER INGELHEIM Category:Blood Clotting (Hemostasis)
Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.
Idarucizumab was developed by Boehringer Ingelheim. One study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation caused by dabigatran within minutes.
It was approved for medical use in the United States and in the European Union in 2015.
* May have multiple approval dates, manufacturers, or labelers.